Acquisition adds navtemadlin, a late-stage rare blood cancer asset in Phase III. This hemato-oncology program in myelofibrosis expands Ipsen’s growing Oncology portfolio; Navtem ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results